Hopp til innhold
Visinnovasjon.no > Aktuelt > New medicines and methods of treatment
VIS logo Logo for VIS
Photo: Camilla Waage, C Foto

New medicines and methods of treatment

We recently published our annual report of 2016, and are now publishing some of the content here on our webpage. In this article you can read about clinical studies, one of our new services.

In 2016, BTO acquired the management of clinical studies at Haukeland University Hospital from Innovest. The business transfer included three senior advisors with several years of experience in managing clinical studies, and an extensive network of researchers, study teams, industry and partners. In addition, we acquired a financial associate.

BTO has a cooperation agreement with Haukeland University Hospital. This agreement states that we will be the contract partner inn all externally funded clinical studies that are planned at the hospital. Haukeland University Hospital is an attractive partner in the implementation of clinical studies, and offers clinical research posts for early-stage studies, modern laboratories and equipment, and study teams with long experience.

– Research shall be an integrated part of the clinical activity at Haukeland University Hospital. The clinical studies increase the opportunity for our patients to try new and pioneering treatment before it reaches the market, and increases the competence in the clinical environment at the hospital, says Clara B. G. Gjesdal, Vice President at Haukeland University Hospital.

BTO’s services in clinical studies range from planning to termination of clinical studies. We contribute by retrieving quotations, budgeting, contracts, accounting, invoicing and travel invoices for patients, as well as archiving etc.

– Clinical studies are essential for the development of new medicines and methods of treatment. By acquiring the management of clinical studies, we aim to work together with national and international businesses to increase the number of patients participating in clinical studies, as well as contributing to even more studies and even better cooperation between business, academia and the hospital. In this way, we can contribute to the solutions of tomorrow, says Anders Haugland, Managing Director at BTO.

During 2016, we were involved in 100 clinical studies. 

You can find The BTO Annual report for 2016 here

A modern pacemaker

In these days, a major international clinical study is being conducted, testing a new type of pacemaker. The pacemaker is today the smallest and most modern pacemaker existing, and it weights only two grams. In comparison, traditional pacemakers weigh ten times as much.

The modern pacemaker does not need charging for twelve years, while the traditional pacemakers lasts only for eight years. It is also easy to replace them when needed, which is a great advantage compared to the traditional pacemakers where a replacement can potentially lead to infections.

In Norway, Haukeland University Hospital was the first to test the modern pacemaker. The first patient was operated in October 2016.

– At Haukeland, 18 people are using the pacemaker, and the results of the study so far are great. None of the patients have experience any complications, says Professor and Chief Physician Svein Færestrand at Haukeland University Hospital.

One of the patients in the study is Solveig (89), who told her story in Bergens Tidende on 28. January 2017. She has got the minipacemaker implanted, which has given her the opportunity to be active again. The pacemaker works like a small computer, and adjusts to her activity. Solveig and the other patients will be further monitored in the study.

3000 patients in Europe are now testing the modern pacemaker

You can find The BTO Annual report for 2016 here